It is reflected by expression of the epithelial growth factor receptor 2 (HER-2) reported in up to 30% of all the patients, but in almost all of the patients diagnosed with ovarian cancer cells at the clinical stage IV [3–8]. Here, ERBB2 is linked to ovarian carcinoma.